Evidence map›Paper›PMID 35361747›Full record

ArticleSignal transduction and targeted therapy2022

Nuclear Aurora kinase A switches m

SiSi Li, YangFan Qi, JiaChuan Yu, YuChao Hao, Bin He, MengJuan Zhang, ZhenWei Dai, TongHui Jiang, SuYi Li, Fang Huang and 21 more

Open access · goldAbstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 4 institutions in 1 country.

SiSi Li *Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
YangFan Qi *Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
JiaChuan Yu *Department of Anesthesiology, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
YuChao Hao *Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Bin He *State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
MengJuan ZhangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
ZhenWei DaiInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
TongHui JiangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
SuYi LiInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Fang HuangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Ning ChenInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Jing WangDepartment of Oncology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China.
MengYing YangDepartment of Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
DaPeng LiangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Fan AnInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
JinYao ZhaoInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
WenJun FanInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
YuJia PanInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
ZiQian DengInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
YuanYuan LuoInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
Tao GuoDepartment of Thoracic surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
Fei PengInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
ZhiJie HouInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
ChunLi WangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
FeiMeng ZhengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
LingZhi XuDepartment of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Jie XuInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
QingPing WenDepartment of Anesthesiology, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
BiLian JinInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China. bjinmcg@foxmail.com.
Yang WangInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China. yangwang@dmu.edu.cn.ORCID 0000-0001-9385-7393
Quentin LiuInstitute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China. liuq9@mail.sysu.edu.cn.
Dalian Medical University · CNSun Yat-sen University · CNHarbin Medical University · CNFirst Affiliated Hospital of Gannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant RNA splicing produces alternative isoforms of genes to facilitate tumor progression, yet how this process is regulated by oncogenic signal remains largely unknown. Here, we unveil that non-canonical activation of nuclear AURKA promotes an oncogenic RNA splicing of tumor suppressor RBM4 directed by m

Indexed as

Alternative SplicingAurora Kinase ANerve Tissue ProteinsRNA-Binding ProteinsRNA Splicing FactorsCell NucleusRNA SplicingAurora Kinase ANerve Tissue ProteinsRNA-Binding ProteinsRNA Splicing Factors

Identifiers

PMID35361747
PMCPMC8971511
OpenAlexW4220968627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.